How to treat borderline resectable pancreatic cancer: current challenges and future directions.

about

How to treat borderline resectable pancreatic cancer: current challenges and future directions.

Item

http://www.wikidata.org/entity/Q47728528

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

How to treat borderline resect ...... llenges and future directions.

@en

How to treat borderline resect ...... llenges and future directions.

@nl

type

Item

label

How to treat borderline resect ...... llenges and future directions.

@en

How to treat borderline resect ...... llenges and future directions.

@nl

prefLabel

How to treat borderline resect ...... llenges and future directions.

@en

How to treat borderline resect ...... llenges and future directions.

@nl

P1476

How to treat borderline resect ...... llenges and future directions.

@en

P2093

Shinichiro Takahashi

http://www.w3.org/2001/XMLSchema#string

P2860

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

Surgical treatment of resectable and borderline resectable pancreatic cancer: expert consensus statement by Evans et al.

Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.

A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer.

Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.

Neoadjuvant gemcitabine-based accelerated hyperfractionation chemoradiotherapy for patients with borderline resectable pancreatic adenocarcinoma.

Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.

Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer.

P31

scholarly article

P356

10.1093/JJCO/HYX191

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29340601

http://www.w3.org/2001/XMLSchema#string